World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
92
Citations
59864
World Ranking
11062
National Ranking
5691

Kanti R. Rai publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Kanti R. Rai sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 484 publications — 55th percentile

55% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Kanti R. Rai D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Kanti R. Rai sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 92 D-Index — 45th percentile

45% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

What is she best known for?

The fields of study she is best known for:

  • Cancer
  • Internal medicine
  • Gene

Kanti R. Rai mostly deals with Chronic lymphocytic leukemia, Immunology, Leukemia, Internal medicine and Antibody. Her Chronic lymphocytic leukemia study combines topics in areas such as Cancer research, Clinical trial, Untreated Chronic Lymphocytic Leukemia, Fludarabine and Disease. Her work deals with themes such as Telomere, Telomerase and Gene mutation, which intersect with Immunology.

Her work carried out in the field of Leukemia brings together such families of science as Lymphoma, In vivo and CD38. Her Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology, Surgery and Oncology. The study incorporates disciplines such as T cell and breakpoint cluster region in addition to Antibody.

Her most cited work include:

  • Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia (4145 citations)
  • Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines (2519 citations)
  • Clinical staging of chronic lymphocytic leukemia. (2355 citations)

What are the main themes of her work throughout her whole career to date?

Her primary scientific interests are in Chronic lymphocytic leukemia, Immunology, Internal medicine, Cancer research and Leukemia. Her primary area of study in Chronic lymphocytic leukemia is in the field of IGHV@. Immunology is closely attributed to Disease in her study.

Her research investigates the connection between Internal medicine and topics such as Oncology that intersect with problems in Clinical trial. Her Cancer research study incorporates themes from Cell, Cytokine, Cell growth, Ibrutinib and Interleukin 15. Breakpoint cluster region is closely connected to Antigen in her research, which is encompassed under the umbrella topic of Antibody.

She most often published in these fields:

  • Chronic lymphocytic leukemia (99.20%)
  • Immunology (58.45%)
  • Internal medicine (38.17%)

What were the highlights of her more recent work (between 2013-2021)?

  • Chronic lymphocytic leukemia (99.20%)
  • Cancer research (45.73%)
  • Immunology (58.45%)

In recent papers she was focusing on the following fields of study:

Kanti R. Rai mainly investigates Chronic lymphocytic leukemia, Cancer research, Immunology, Internal medicine and Leukemia. Her studies deal with areas such as breakpoint cluster region and CD5, Antibody as well as Chronic lymphocytic leukemia. The concepts of her Cancer research study are interwoven with issues in In vitro, Cytokine, Cell growth, T cell and Interleukin 15.

Her Immunology study frequently draws parallels with other fields, such as Myeloid-derived Suppressor Cell. Her research in Internal medicine intersects with topics in Gastroenterology, Surgery and Oncology. In her study, Clinical trial is inextricably linked to Disease, which falls within the broad field of Leukemia.

Between 2013 and 2021, her most popular works were:

  • iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL (392 citations)
  • Chronic lymphocytic leukaemia. (192 citations)
  • Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia (159 citations)

In her most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Gene

Kanti R. Rai spends much of her time researching Chronic lymphocytic leukemia, Immunology, Leukemia, Internal medicine and Cancer research. Kanti R. Rai studies Ibrutinib which is a part of Chronic lymphocytic leukemia. Her study in T cell, Antibody and B-cell receptor falls within the category of Immunology.

Her Leukemia research integrates issues from Somatic cell, Bruton's tyrosine kinase, Pathogenesis and Somatic evolution in cancer. Her biological study spans a wide range of topics, including Gastroenterology, Surgery and Oncology. Her Cancer research research includes themes of Tyrosine kinase, CD5, DNA methylation and CD38.

Best Publications

  • Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia

    George Adrian Calin;Calin Dan Dumitru;Masayoshi Shimizu;Roberta Bichi

  • Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

    Michael Hallek;Bruce D. Cheson;Daniel Catovsky;Federico Caligaris-Cappio

  • Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

    Rajendra N. Damle;Tarun Wasil;Tarun Wasil;Tarun Wasil;Franco Fais;Franco Fais;Franco Fais;Fabio Ghiotto;Fabio Ghiotto;Fabio Ghiotto

  • Clinical staging of chronic lymphocytic leukemia.

    Kanti R. Rai;Arthur Sawitsky;Eugene P. Cronkite;Arjun D. Chanana

  • National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment

    Bruce D. Cheson;John M. Bennett;Michael Grever;Neil Kay

  • Chronic lymphocytic leukemia.

    Nicholas Chiorazzi;Kanti R. Rai;Manlio Ferrarini

  • Chronic Lymphocytic Leukemia.

    Nicholas Chiorazzi;Shih-Shih Chen;Kanti R. Rai

  • iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

    Michael Hallek;Bruce D. Cheson;Daniel Catovsky;Federico Caligaris-Cappio

  • Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

    Kanti R. Rai;Bercedis L. Peterson;Frederick R. Appelbaum;Jonathan Kolitz

  • Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

    Michael J. Keating;Ian Flinn;Vinay Jain;Jacques-Louis Binet

  • ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia

    Laura Z. Rassenti;Lang Huynh;Tracy L. Toy;Liguang Chen

  • Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.

    Franco Fais;Fabio Ghiotto;Shiori Hashimoto;Brian Sellars

  • Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with in vitro and in vivo chemoresponses

    Shinichi Kitada;Janet Andersen;Sophie Akar;Juan M. Zapata

  • Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

    John C. Byrd;Bercedis L. Peterson;Vicki A. Morrison;Kathleen Park

  • In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells.

    Bradley T. Messmer;Davorka Messmer;Steven L. Allen;Steven L. Allen;Jonathan E. Kolitz;Jonathan E. Kolitz

  • Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.

    Liguang Chen;George Widhopf;George Widhopf;George Widhopf;Lang Huynh;Lang Huynh;Lang Huynh;Laura Rassenti;Laura Rassenti;Laura Rassenti

  • Chronic lymphocytic leukaemia.

    Thomas J. Kipps;Freda K. Stevenson;Catherine J. Wu;Carlo M. Croce

  • Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

    John C. Byrd;Kanti Rai;Bercedis L. Peterson;Frederick R. Appelbaum

  • Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

    KR Rai;JF Holland;OJ Glidewell;V Weinberg

  • Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute-sponsored working group

    Bruce D. Cheson;John M. Bennett;Kanti R. Rai;Michael R. Grever

Frequent Co-Authors

Nicholas Chiorazzi
Nicholas Chiorazzi Feinstein Institute for Medical Research
Jonathan E. Kolitz
Jonathan E. Kolitz Hofstra University
Thomas J. Kipps
Thomas J. Kipps University of California, San Diego
John C. Byrd
John C. Byrd University of Pittsburgh Cancer Institute
Laura Z. Rassenti
Laura Z. Rassenti University of California, San Diego
Jennifer R. Brown
Jennifer R. Brown Harvard University
Michael J. Keating
Michael J. Keating The University of Texas MD Anderson Cancer Center
Neil E. Kay
Neil E. Kay Mayo Clinic
John G. Gribben
John G. Gribben Queen Mary University of London
Richard A. Larson
Richard A. Larson University of Chicago

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical career in the USA doesn't just mean attending traditional medical school. Many healthcare professionals explore flexible online degrees to expand their skills or pivot into new roles. For registered nurses interested in a mental health specialty, bsn to np programs online offer accelerated paths to become nurse practitioners with a psychiatric-mental health focus.

If you're drawn to leadership and policy, a health care administration online degree is an effective way to enter the fast-growing field of healthcare management. For those seeking to advance their careers further, consider one of the most affordable online mha programs, which can open doors to senior roles across diverse healthcare settings.

Practicing nurses aiming for the highest level of clinical expertise may benefit from msn to dnp programs online. These programs prepare you for leadership and advanced practice roles while accommodating busy work schedules. Exploring these online pathways offers accessibility, flexibility, and a variety of specialized career options within medicine and healthcare.

Best Scientists Citing Kanti R. Rai

Trending Scientists

Recently Published Articles